EPS for Keryx Biopharmaceuticals, Inc. (KERX) Expected At $-0.13

November 1, 2018 – By Dolores Ford

Investors sentiment increased to 1.74 in Q2 2018. Its up 0.74, from 1 in 2018Q1. It is positive, as 9 investors sold Keryx Biopharmaceuticals, Inc. shares while 26 reduced holdings. 23 funds opened positions while 38 raised stakes. 71.09 million shares or 2.95% less from 73.25 million shares in 2018Q1 were reported.
Royal State Bank Of Canada has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Schwab Charles Management Inc holds 0% or 549,724 shares in its portfolio. Art Advisors Ltd Co has invested 0.01% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Moreover, Blair William And Il has 0% invested in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) for 194,900 shares. Rice Hall James & invested in 0.31% or 2.28M shares. Wealthtrust Fairport Limited Liability reported 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Prudential Fincl Inc reported 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Mbadachusetts-based Rhumbline Advisers has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Brandywine Global Inv Mgmt Ltd Limited Liability Company holds 163,984 shares. Hanson Mcclain, California-based fund reported 2,000 shares. Proshare Advisors Lc stated it has 12,450 shares. Piedmont Invest Advsrs Limited Liability Corporation invested 0% of its portfolio in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Creative Planning has invested 0% in Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX). Susquehanna International Grp Ltd Liability Partnership holds 88,499 shares. First Republic Investment Inc holds 30,528 shares or 0% of its portfolio.

Since May 15, 2018, it had 0 insider purchases, and 9 selling transactions for $60,251 activity. Another trade for 1,333 shares valued at $6,958 was sold by GILMAN STEVEN C. $6,589 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) was sold by Neylan John F. on Tuesday, May 15. Shares for $3,602 were sold by Holmes Scott A on Wednesday, August 15. On Wednesday, July 18 Carberry Christine A. sold $9,074 worth of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) or 2,021 shares.

Analysts expect Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) to report $-0.13 EPS on November, 6.They anticipate $0.07 EPS change or 35.00 % from last quarter’s $-0.2 EPS. The stock decreased 3.14% or $0.09 during the last trading session, reaching $2.78. About 636,636 shares traded. Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) has declined 58.70% since November 1, 2017 and is downtrending. It has underperformed by 74.32% the S&P500.

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Ratings Coverage

Among 4 badysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Keryx Biopharmaceuticals had 4 badyst reports since June 25, 2018 according to SRatingsIntel. The rating was maintained by Citigroup with “Neutral” on Thursday, August 9. Maxim Group downgraded the shares of KERX in report on Thursday, June 28 to “Hold” rating.

Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with renal disease in the United States. The company has market cap of $334.88 million. It markets its lead product Auryxia , an orally available, absorbable, iron medicine for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. It currently has negative earnings. The firm has licensing and collaboration agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Auryxia in Japan.

More news for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) were recently published by: Nasdaq.com, which released: “Keryx Biopharmaceuticals Announces Filing of Definitive Joint Proxy Statement in Connection with Pending Merger …” on October 30, 2018. Digitaljournal.com‘s article titled: “NASDAQ: KERX Investor Alert: Lawsuit Filed Against Acquisition by Keryx Biopharmaceuticals, Inc.” and published on October 23, 2018 is yet another important article.

By Dolores Ford